CardioGenics Holdings Inc (CGNH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CardioGenics Holdings Inc (CGNH) trades at $0.00. CardioGenics Holdings Inc. develops and commercializes diagnostic test products for the in vitro diagnostics testing market. Market cap: $12,000, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CGNH: CGNH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CGNH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CGNH: 1/1 perspectives are bearish.
How is this calculated? →CardioGenics Holdings Inc (CGNH) Healthcare & Pipeline Overview
CardioGenics Holdings Inc. focuses on point-of-care diagnostic solutions, offering the QL Care Analyzer and a range of immunoassay tests. Targeting the in vitro diagnostics market, the company aims to provide rapid and accurate diagnostic tools for cardiac markers and other applications, primarily across the United States, Canada, and Europe.
What Is the Investment Thesis for CGNH?
CardioGenics Holdings Inc. presents a high-risk, high-reward investment profile due to its focus on the point-of-care diagnostics market. The company's QL Care Analyzer and cardiac marker tests address a critical need for rapid and accurate diagnostics. A key value driver is the potential for widespread adoption of the QL Care Analyzer in hospitals and clinics. Growth catalysts include regulatory approvals in key markets and strategic partnerships for distribution. However, the company faces significant challenges, including limited financial resources, intense competition, and the need for successful commercialization of its products. With a market capitalization of 12K and a beta of 20.77, CGNH exhibits substantial volatility. Successful execution of its commercialization strategy is crucial for realizing its potential.
Based on FMP financials and quantitative analysis
CGNH Key Highlights
- CardioGenics Holdings Inc. operates in the in vitro diagnostics market, focusing on point-of-care testing.
- The company's QL Care Analyzer is a portable, automated immunoassay analyzer designed for rapid results.
- CardioGenics offers immunoassay tests for cardiac markers, aiding in the diagnosis of heart attacks.
- The company's products target markets in the United States, Canada, and Europe.
- CardioGenics faces strong competition and requires successful commercialization to achieve growth.
Who Are CGNH's Competitors?
CGNH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CGNH's Key Strengths?
- Proprietary QL Care Analyzer technology
- Focus on point-of-care testing
- Potential for rapid diagnostic results
- Production of paramagnetic beads
What Are CGNH's Weaknesses?
- Limited financial resources
- Small number of employees
- Dependence on single product line
- OTC market listing
What Could Drive CGNH Stock Higher?
- Regulatory approvals for QL Care Analyzer in new markets.
- Strategic partnerships for distribution and commercialization.
- Development of new diagnostic tests for the QL Care Analyzer platform.
- Increasing demand for point-of-care testing solutions.
What Are the Key Risks for CGNH?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Limited financial resources to support commercialization efforts.
- Intense competition from established players in the in vitro diagnostics market.
- Regulatory hurdles and approval processes for new products.
- Dependence on the success of the QL Care Analyzer platform.
- OTC market listing and associated risks.
What Are the Growth Opportunities for CGNH?
- Expansion into New Geographic Markets: CardioGenics has the opportunity to expand its market presence beyond its current focus on the United States, Canada, and Europe. Emerging markets in Asia and Latin America represent significant growth potential, driven by increasing healthcare spending and a growing demand for advanced diagnostic solutions. Successful entry into these markets would require strategic partnerships with local distributors and regulatory approvals. This expansion could significantly increase revenue within the next 3-5 years.
- Development of New Diagnostic Tests: CardioGenics can leverage its QL Care Analyzer platform to develop and commercialize new diagnostic tests for a wider range of diseases and conditions. Expanding its test menu would increase the value proposition of the QL Care Analyzer and attract a broader customer base. Potential areas for expansion include infectious diseases, oncology, and autoimmune disorders. Investment in research and development is crucial for realizing this growth opportunity, with new tests potentially adding significant revenue streams in the next 2-4 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with hospitals, clinics, and other healthcare providers can accelerate the adoption of CardioGenics' products and expand its market reach. Collaborations with research institutions can also facilitate the development of new diagnostic tests and technologies. These partnerships can provide access to new markets, distribution channels, and expertise, driving revenue growth and enhancing the company's competitive position. Such partnerships could materialize within the next 1-2 years.
- Increased Focus on Point-of-Care Testing: The demand for point-of-care testing is increasing due to its ability to provide rapid results and improve patient outcomes. CardioGenics is well-positioned to capitalize on this trend with its QL Care Analyzer. By focusing on the development and commercialization of POC diagnostic solutions, the company can capture a larger share of the in vitro diagnostics market. This strategy requires continued innovation and effective marketing to highlight the benefits of POC testing. This focus can yield increased market share within the next 2-3 years.
- Leveraging Paramagnetic Beads Technology: CardioGenics' production of paramagnetic beads for immunoassay tests presents a growth opportunity by expanding its customer base to clinical and research laboratories. By marketing these beads to a wider range of labs, CardioGenics can generate additional revenue streams. This requires targeted marketing efforts and potentially expanding production capacity to meet increased demand. This could lead to increased sales in the next 1-2 years.
What Opportunities Does CGNH Have?
- Expansion into new geographic markets
- Development of new diagnostic tests
- Strategic partnerships and collaborations
- Increased demand for point-of-care testing
What Threats Does CGNH Face?
- Intense competition from established players
- Regulatory hurdles and approval processes
- Technological obsolescence
- Economic downturn affecting healthcare spending
What Are CGNH's Competitive Advantages?
- Proprietary QL Care Analyzer technology.
- Focus on point-of-care testing market.
- Development of specific immunoassay tests for cardiac markers.
- Production of paramagnetic beads for immunoassay applications.
What Does CGNH Do?
CardioGenics Holdings Inc., originally founded in 1997 as Jag Media Holdings, transitioned to its current focus on in vitro diagnostics in 2009. The company develops and commercializes diagnostic test products, with a focus on point-of-care (POC) solutions. Its flagship product is the QL Care Analyzer, a portable, stand-alone, and automated immunoassay analyzer. This system utilizes proprietary self-metering cartridges to perform immunoassay tests directly at the point of care, enabling rapid results. CardioGenics also offers a series of immunoassay tests designed to identify cardiac markers in the blood, crucial for the timely diagnosis of heart attacks. Additionally, the company produces paramagnetic beads used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. CardioGenics aims to improve diagnostic accuracy and speed, particularly in critical care settings. Headquartered in Mississauga, Canada, the company targets markets in the United States, Canada, and Europe.
What Products and Services Does CGNH Offer?
- Develop and commercialize diagnostic test products.
- Focus on in vitro diagnostics testing market.
- Offer the QL Care Analyzer, a portable immunoassay analyzer.
- Provide immunoassay tests to identify cardiac markers.
- Produce paramagnetic beads for use in immunoassay tests.
- Target point-of-care testing applications.
How Does CGNH Make Money?
- Sales of QL Care Analyzer systems to hospitals and clinics.
- Sales of immunoassay test cartridges for use with the QL Care Analyzer.
- Sales of paramagnetic beads to clinical and research laboratories.
- Potential revenue from service and maintenance contracts for the QL Care Analyzer.
What Industry Does CGNH Operate In?
CardioGenics Holdings Inc. operates within the in vitro diagnostics market, a segment of the broader healthcare industry experiencing steady growth driven by technological advancements and increasing demand for rapid and accurate diagnostic testing. The point-of-care diagnostics sub-segment is particularly attractive, offering the potential for faster turnaround times and improved patient outcomes. However, the market is highly competitive, with established players like BMGP and HLUN holding significant market share. CardioGenics must differentiate itself through innovative technology, strategic partnerships, and effective commercialization to succeed.
Who Are CGNH's Key Customers?
- Hospitals and clinics requiring point-of-care diagnostic solutions.
- Clinical laboratories performing immunoassay tests.
- Research laboratories using immunoassay techniques.
- Healthcare providers seeking rapid and accurate diagnostic results.
Company Profile
CardioGenics Holdings Inc operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Mississauga, CA. The company is led by CEO Yahia Abdul Gawad. CGNH has traded publicly since 2004.
How CardioGenics Holdings Inc Is Valued
CardioGenics Holdings Inc carries a market capitalization of 12K, placing it in the micro-cap category.
ROE 141%Key Financial Metrics
Return on equity for CardioGenics Holdings Inc stands at 141.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
CardioGenics Holdings Inc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CGNH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CGNH Latest News
No recent news available for CGNH.
CGNH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CGNH.
Price Targets
Wall Street price target analysis for CGNH.
CGNH MoonshotScore
What does this score mean?
The MoonshotScore rates CGNH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yahia Abdul Gawad
CEO
Yahia Abdul Gawad serves as the CEO of CardioGenics Holdings Inc. Information regarding his detailed career history and educational background is not available in the provided data. As CEO, he is responsible for leading the company's strategic direction and overseeing its operations in the development and commercialization of diagnostic test products.
Track Record: Due to limited information, Yahia Abdul Gawad's specific achievements and strategic decisions as CEO of CardioGenics Holdings Inc. cannot be detailed. His tenure involves navigating the company's focus on point-of-care diagnostics and managing a small team of employees.
CGNH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CardioGenics Holdings Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Limited regulatory oversight
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Understand the company's capital structure and ownership.
- Consult with a qualified financial advisor.
- Company has been in operation since 1997.
- Focus on developing and commercializing diagnostic test products.
- QL Care Analyzer and immunoassay tests address a specific market need.
- Headquartered in Mississauga, Canada.
Common Questions About CGNH (Healthcare)
What does CardioGenics Holdings Inc do?
CardioGenics Holdings Inc. is a healthcare company focused on developing and commercializing diagnostic test products for the in vitro diagnostics market. Their primary product is the QL Care Analyzer, a portable, automated point-of-care immunoassay analyzer. This device, along with their range of immunoassay tests, aims to provide rapid and accurate diagnostic results, particularly for cardiac markers, enabling faster and more effective treatment decisions in critical care settings. They also produce paramagnetic beads used in clinical and research laboratories.
What are the main risks for CGNH?
CardioGenics Holdings Inc. faces several key risks. These include limited financial resources, intense competition in the in vitro diagnostics market, regulatory hurdles for product approvals, and dependence on the success of the QL Care Analyzer platform. As an OTC-listed company, CGNH also faces risks associated with lower liquidity, limited disclosure requirements, and potential for price volatility. Successful navigation of these risks is crucial for the company's long-term viability.
What are the key factors to evaluate for CGNH?
Evaluate CGNH on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does CGNH data refresh on this page?
CGNH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CGNH's recent stock price performance?
CardioGenics Holdings Inc (CGNH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary QL Care Analyzer technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CGNH overvalued or undervalued right now?
Valuing CardioGenics Holdings Inc (CGNH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CGNH?
Before investing in CardioGenics Holdings Inc (CGNH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CGNH to a portfolio?
Key strength of CardioGenics Holdings Inc (CGNH): Proprietary QL Care Analyzer technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for CardioGenics Holdings Inc.
- AI analysis pending for CGNH.